221 related articles for article (PubMed ID: 25286028)
61. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
[TBL] [Abstract][Full Text] [Related]
62. Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice.
Qi S; Li B; Yang T; Liu Y; Cao S; He X; Zhang P; Li L; Xu C
Int J Mol Sci; 2014 Nov; 15(11):20004-21. PubMed ID: 25372945
[TBL] [Abstract][Full Text] [Related]
63. A genome-wide enrichment screen identifies NUMA1-loss as a resistance mechanism against mitotic cell-death induced by BMI1 inhibition.
Gisler S; Maia ARR; Chandrasekaran G; Kopparam J; van Lohuizen M
PLoS One; 2020; 15(4):e0227592. PubMed ID: 32343689
[TBL] [Abstract][Full Text] [Related]
64. Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma.
Diao P; Ge H; Song Y; Wu Y; Li J; Li Z; Yang J; Wang Y; Cheng J
J Cell Mol Med; 2019 Jun; 23(6):4269-4280. PubMed ID: 30950191
[TBL] [Abstract][Full Text] [Related]
65. Co-inhibition of BMI1 and Mel18 enhances chemosensitivity of esophageal squamous cell carcinoma
Wang J; Ji H; Zhu Q; Yu X; Du J; Jiang Z
Oncol Lett; 2019 Jun; 17(6):5012-5022. PubMed ID: 31186712
[TBL] [Abstract][Full Text] [Related]
66. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Zhao Q; Qian Q; Cao D; Yang J; Gui T; Shen K
J Ovarian Res; 2018 Apr; 11(1):31. PubMed ID: 29685168
[TBL] [Abstract][Full Text] [Related]
67. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
68. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
Griffith J; Andrade D; Mehta M; Berry W; Benbrook DM; Aravindan N; Herman TS; Ramesh R; Munshi A
Oncol Rep; 2017 Apr; 37(4):2382-2390. PubMed ID: 28260023
[TBL] [Abstract][Full Text] [Related]
69. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Proctor E; Waghray M; Lee CJ; Heidt DG; Yalamanchili M; Li C; Bednar F; Simeone DM
PLoS One; 2013; 8(2):e55820. PubMed ID: 23437065
[TBL] [Abstract][Full Text] [Related]
70. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
Chang YC; Jan CI; Peng CY; Lai YC; Hu FW; Yu CC
Oncotarget; 2015 Sep; 6(27):24002-16. PubMed ID: 26090866
[TBL] [Abstract][Full Text] [Related]
71. CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia.
Mariani SA; Minieri V; De Dominici M; Iacobucci I; Peterson LF; Calabretta B
Leukemia; 2016 Aug; 30(8):1682-90. PubMed ID: 27125204
[TBL] [Abstract][Full Text] [Related]
72. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer.
Zhang XW; Sheng YP; Li Q; Qin W; Lu YW; Cheng YF; Liu BY; Zhang FC; Li J; Dimri GP; Guo WJ
Mol Cancer; 2010 Feb; 9():40. PubMed ID: 20170541
[TBL] [Abstract][Full Text] [Related]
73. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
74. Cancer-associated fibroblasts confer cisplatin resistance of tongue cancer via autophagy activation.
Liao JK; Zhou B; Zhuang XM; Zhuang PL; Zhang DM; Chen WL
Biomed Pharmacother; 2018 Jan; 97():1341-1348. PubMed ID: 29156523
[TBL] [Abstract][Full Text] [Related]
75. Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients' prognosis.
Wei Z; Wang Y; Li Z; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Wu Y; Cheng J
J Oral Pathol Med; 2013 Nov; 42(10):747-54. PubMed ID: 23551691
[TBL] [Abstract][Full Text] [Related]
76. MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4.
Ren W; Wang X; Gao L; Li S; Yan X; Zhang J; Huang C; Zhang Y; Zhi K
Mol Cell Biochem; 2014 May; 390(1-2):253-62. PubMed ID: 24609942
[TBL] [Abstract][Full Text] [Related]
77. Joining Forces: Bmi1 Inhibition and Cisplatin Curb Squamous Carcinogenesis.
Brown JA; Schober M
Cell Stem Cell; 2017 May; 20(5):575-577. PubMed ID: 28475877
[TBL] [Abstract][Full Text] [Related]
78. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
79. miR-145-5p Targets Sp1 in Non-Small Cell Lung Cancer Cells and Links to BMI1 Induced Pemetrexed Resistance and Epithelial-Mesenchymal Transition.
Chang WW; Wang BY; Chen SH; Chien PJ; Sheu GT; Lin CH
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499676
[TBL] [Abstract][Full Text] [Related]
80. Circular RNA BMI1 Serves as a Potential Target for Diagnosis and Treatment in Esophageal Cancer.
Zhao Q; Zhu X; Ke JM; Su XY; Yi J; Wu DL; Lin J; Deng ZQ
Technol Cancer Res Treat; 2021; 20():15330338211033075. PubMed ID: 34278876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
